AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04881305 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaires and neuropsychological assessment
Description: Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
Study NCT05371951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia HLS
Description: 84 procedure administrations with the Erchonia® HLS™ administered by the subject at home: twice daily procedure administrations for 6 weeks.
Study NCT05626959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTI164
Description: Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Study NCT05300594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant extracts, vitamins and mineral
Description: Day tablet every day during 3 months : Magnesium (75 mg), Ginkgo Biloba extract (40 mg), hawthorn extract (37,5 mg), L-Theanin (50 mg) , Niacin (16mg), Quercetin (25mg), B12 Vitamin (2,5 µg), B6 Vitamin (1,4 mg), Thiamin (1,1 mg)~Night tablet every evening during 3 months : Magnesium (37,5 mg), Ginkgo Biloba extract (40 mg), Eschscholzia californica extract (40 mg), Zinc (10 mg), Melatonin (1mg), Lemon balm extract (80 mg), Tryptocetyn (65 mg)
Study NCT05300594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day tablet every morning during 3 months : Excipients; Night tablet every evening during 3 months : Excipients
Study NCT05626959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NTI164
Description: Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Study NCT05330429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT05478096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetStarted
Description: Guided internet-based intervention for procrastination.
Study NCT05330429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered intravenously
Study NCT05330429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously
Study NCT05330429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Administered intravenously
Study NCT05330429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered intravenously
Study NCT06153563 — intervention group
Intervention type: OTHER
Intervention: Data collection on patient history and intraoperative results.
Description: Data collection on patient history and intraoperative results.
Study NCT06407648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Assessments
Description: Personalized CBT will use individualized OCD symptom networks to guide CBT strategies to target central symptom nodes in contemporaneous networks.
Study NCT06407648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard CBT condition will use standard-of-care approaches to guide CBT strategies to target OCD symptoms.
Study NCT05377476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery training
Description: Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation.
Study NCT05377476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation training
Description: Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation.
Study NCT05377476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard rehabilitation
Description: 40 minutes of standard rehabilitation.
Study NCT05377476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard rehabilitation
Description: 40 minutes of standard rehabilitation.
Study NCT06344052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-002
Description: SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
Study NCT06344052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
Study NCT06344052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vismodegib
Description: The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
Study NCT06506175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 tablets
Description: HRS9531 tablets
Study NCT06401616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAC will be discontinued for the duration of the trial
Description: Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
Study NCT05330429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Administered intravenously
Study NCT05330429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered intravenously
Study NCT05330429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Administered intravenously
Study NCT05330429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously
Study NCT06085404 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
Study NCT06150352 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure or other management for OSA per clinical indications.
Description: PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria
Study NCT05643170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
Study NCT04706715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-REGN3767
Description: Anti-LAG-3 PET imaging tracer
Study NCT05570227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [U-13C]Glucose Infusion
Description: Peri-operative infusion of \[U-13C\]glucose
Study NCT04706715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
Study NCT05588076 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04953663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: it-hMSC
Description: Different doses of it-hMSC
Study NCT05625230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation plus Dynamic Mental Imagery
Description: This intervention consists of an 8-session behavioural activation treatment with an added dynamic imagery exercise after each session. The dynamic imagery exercise is structured as follows: (1) the therapist explains the intervention; (2) the therapist models dynamic simulation skill (dynamic imagery) and repeats with the participant while giving appropriate feedback; (3) the participant completes a 10-minute Kinect training; (4) the participant completes a short Actfulness exercise that involves focusing on the feelings of movements of breathing and hands and dynamic imagery of one planned activity. From the second session, participants memorize daily activities forming a short dynamic memory of the activity focusing on feelings of movements.
Study NCT05625230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral activation
Description: The BA intervention is a short 8 session behavioural intervention. Participants learn to monitor the activities, plan anti-depressant activities for the next week and find support for the implementation of the activity.
Study NCT05710211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clonal architecture determination
Description: Biological:~* Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing~* Secondary outcome: transcriptomic study by RNA-sequencing
Study NCT06353399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-marrow penetrations
Description: Intra-marrow penetrations
Study NCT06353399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Intra-marrow penetrations
Description: No Intra-marrow penetrations
Study NCT04837729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
Study NCT05368103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daxdilimab
Description: Daxdilimab will be administered subcutaneously as two injections for each dose.
Study NCT05089448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alisartan, Amlodipine besylate
Description: Drugs will be taken once daily at 6:00-10:00.
Study NCT05089448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisartan, Amlodipine besylate
Description: Drugs will be taken once daily at 20:00-24:00.
Study NCT04907149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 film-coated tablet
Description: Participants will receive a single oral dose of GLPG3970.
Study NCT04907149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]GLPG3970 solution for infusion
Description: Participants will receive an i.v. microtracer microdose.
Study NCT04907149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14]GLPG3970 oral solution
Description: Participants will receive a single oral dose \[14C\]GLPG3970.
Study NCT04953663 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: it-hMSC
Description: Different doses of it-hMSC
Study NCT06300294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: After the CAG procedure, acupressure will be applied to individuals whose vital signs are within the normal range.
Study NCT06239519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Practice + JoyPop
Description: Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
Study NCT05277701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
Study NCT05384821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV, D1-D22-D43 and D64
Study NCT05384821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
Study NCT05384821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
Study NCT05384821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
Study NCT05384821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-Retinoic acid
Description: Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
Study NCT05123079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darigabat
Description: Tablets
Study NCT04919694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combination of orbital compression surgery and strabismus surgery
Description: combination of orbital compression surgery and strabismus surgery at the same time
Study NCT04919694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orbital compression
Description: orbital compression
Study NCT04443517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alpha Optimization
Description: Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of desflurane and opioid.
Study NCT04443517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Optimization
Description: Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of desflurane and opioid.
Study NCT04443517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emergence from anesthesia with propofol
Description: Infusion of 400 mg/h of propofol during the final 10-20 minutes of surgery. Total doses of propofol administered are likely to be in the range of 1-3 mg/kg.
Study NCT04443517 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emergence from anesthesia with propofol
Description: Infusion of 400 mg/h of propofol during the final 10-20 minutes of surgery. Total doses of propofol administered are likely to be in the range of 1-3 mg/kg.
Study NCT05237999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KopOpOuders-PTSD
Description: See arm description
Study NCT06327282 — intervention group
Intervention type: BEHAVIORAL
Intervention: education on pain and related knowledge
Description: Before surgery, pain related knowledge was educated.
Study NCT04864834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOK583A1 (40 mg/mL)
Description: IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
Study NCT04864834 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eylea EU (40 mg/mL)
Description: IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
Study NCT04955574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SH-DS01 + Antibiotic Placebo
Description: Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
Study NCT04955574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-DS01 + Metronidazole
Description: Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of 500mg metronidazole twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
Study NCT04955574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Placebo + Antibiotic Placebo
Description: Participants will be instructed to take 2 capsules of placebo for probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of placebo for probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
Study NCT05864391 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AZD7503
Description: Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
Study NCT02441777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polarization-Sensitive OFDI
Description: OCT Imaging of the eye
Study NCT06276439 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical removal of breast cancer and lymph nodes
Description: The patients will undergo a surgical procedure to remove tumor tissue in the breast and its associated lymph nodes. No clinical decision is based on the imaging device tested.
Study NCT04673331 — intervention group
Intervention type: OTHER
Intervention: exercise capacity
Description: 3minute step test and 1minute sit to stand test used assessment of exercise capacity.
Study NCT01503281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training
Description: Aerobic and resistance training exercises + Mediterranean diet
Study NCT06441344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Anlotinib
Description: For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used
Study NCT06441344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used
Study NCT05653661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsies
Study NCT05653661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05653661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans
Study NCT05653661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scans
Study NCT05653661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel/Danburstotug Complex AP160
Description: Given IV
Study NCT06505850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tapered-shaped cuff tracheal tube
Description: Tracheal intubation with a tapered-shaped cuff tube
Study NCT06505850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylindrical-shaped cuff tracheal tube
Description: Tracheal intubation with a cylindrical-shaped cuff tube
Study NCT06565078 — intervention group
Intervention type: DRUG
Intervention: Immune Globulin Subcutaneous (Human), 20% Solution
Description: CUVITRU 20% Solution
Study NCT05056688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testicular Model BSE/TSE Training Set
Description: The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
Study NCT06105086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-structured interview
Description: Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
Study NCT05713903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy
Description: Resection of the ascending colon via a laparoscopic approach, adhering to the CME principles
Study NCT05713903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open right colectomy
Description: Resection of the ascending colon via an open approach, adhering to the CME principles
Study NCT06306651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula therapy group
Description: Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC